Form 4: Dynavax Technologies Corp: SVP General Counsel John L. Slebir Reports Stock Transactions

John L. Slebir, SVP General Counsel of Dynavax Technologies Corp, reports acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, on February 13, 2025.

Summary

• On February 13, 2025, John L. Slebir, the SVP General Counsel of Dynavax Technologies Corp, filed a Form 4 detailing changes in beneficial ownership.
• The transactions included the vesting of 14,000 Restricted Stock Units (RSUs) which converted into common stock.
• 4,708 shares were withheld by Dynavax to cover tax obligations related to the RSU vesting at a price of $12.69.
• Slebir also acquired 70,000 stock options with an exercise price of $12.69, vesting over three years, and 42,424 RSUs vesting over three years.
• Following these transactions, Slebir directly owns 25,064 shares of common stock and holds derivative securities including 70,000 stock options and 42,424 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports routine stock transactions by an executive. The granting of options and RSUs is generally a positive sign, but the tax withholding is a neutral event.

Positives

• The granting of stock options and RSUs to a key executive suggests an incentive alignment with the company's long-term performance.
• The vesting of RSUs indicates the achievement of certain performance conditions.

Future Outlook

The vesting schedule of the RSUs and stock options indicates a multi-year incentive structure for the reporting person.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the biotechnology industry to align management interests with shareholder value and incentivize long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often vesting over 3-4 years.
• RSUs are also commonly used, with vesting contingent on performance or time-based milestones, similar to companies like Moderna or BioNTech.
• The size of the grant (70,000 options and 42,424 RSUs) would need to be compared to similar-sized biotech companies to assess its relative magnitude.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• Employees may be indirectly impacted by the vesting of RSUs if it reflects the achievement of company performance goals.

Key Dates